WO1999045908A3 - Anti-viral uses of leflunomide products - Google Patents

Anti-viral uses of leflunomide products Download PDF

Info

Publication number
WO1999045908A3
WO1999045908A3 PCT/US1999/005326 US9905326W WO9945908A3 WO 1999045908 A3 WO1999045908 A3 WO 1999045908A3 US 9905326 W US9905326 W US 9905326W WO 9945908 A3 WO9945908 A3 WO 9945908A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral
viral uses
leflunomide
products
leflunomide products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/005326
Other languages
French (fr)
Other versions
WO1999045908A2 (en
Inventor
James W Williams
Anita Chong
W James Waldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Priority to US09/529,053 priority Critical patent/US7691890B2/en
Priority to HK02105067.5A priority patent/HK1045251A1/en
Priority to JP2000535323A priority patent/JP4581137B2/en
Priority to EP99912426A priority patent/EP1169036B1/en
Priority to DE69937904T priority patent/DE69937904T2/en
Priority to AU30802/99A priority patent/AU3080299A/en
Publication of WO1999045908A2 publication Critical patent/WO1999045908A2/en
Publication of WO1999045908A3 publication Critical patent/WO1999045908A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to anti-viral uses of leflunomide product, alone or in combination with other anti-viral agents, or in combination with a pyrimidine such as uridine.
PCT/US1999/005326 1998-03-11 1999-03-11 Anti-viral uses of leflunomide products Ceased WO1999045908A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US09/529,053 US7691890B2 (en) 1998-03-11 1999-03-11 Anti-viral uses of leflunomide products
HK02105067.5A HK1045251A1 (en) 1998-03-11 1999-03-11 Anti-viral uses of leflunomide products
JP2000535323A JP4581137B2 (en) 1998-03-11 1999-03-11 Antiviral use of leflunomide products
EP99912426A EP1169036B1 (en) 1998-03-11 1999-03-11 Anti-viral uses of leflunomide products
DE69937904T DE69937904T2 (en) 1998-03-11 1999-03-11 ANTIVIRAL USES OF LEFLUNOMID PRODUCTS
AU30802/99A AU3080299A (en) 1998-03-11 1999-03-11 Anti-viral uses of leflunomide products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7755298P 1998-03-11 1998-03-11
US60/077,552 1998-03-11

Publications (2)

Publication Number Publication Date
WO1999045908A2 WO1999045908A2 (en) 1999-09-16
WO1999045908A3 true WO1999045908A3 (en) 2000-01-20

Family

ID=22138741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/005326 Ceased WO1999045908A2 (en) 1998-03-11 1999-03-11 Anti-viral uses of leflunomide products

Country Status (7)

Country Link
EP (1) EP1169036B1 (en)
JP (1) JP4581137B2 (en)
AT (1) ATE382349T1 (en)
AU (1) AU3080299A (en)
DE (1) DE69937904T2 (en)
HK (1) HK1045251A1 (en)
WO (1) WO1999045908A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151188A0 (en) * 2000-02-28 2003-04-10 Bayer Ag Medicament for viral diseases
JP2005104852A (en) * 2003-09-29 2005-04-21 Kyowa Hakko Kogyo Co Ltd Composition for prevention or treatment of morbillivirus infection
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
US20230097553A1 (en) * 2020-02-18 2023-03-30 East China University Of Science And Technology Anti-rna virus drug and application thereof
WO2022171682A1 (en) * 2021-02-10 2022-08-18 Phytobokaz Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections
FR3119539B1 (en) * 2021-02-10 2023-12-22 Phytobokaz Therapeutic composition inhibiting DHODH

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607775A2 (en) * 1993-01-08 1994-07-27 Hoechst Aktiengesellschaft Use of leflunomid for the inhibition of interleukin 1 beta
EP0607776A2 (en) * 1993-01-08 1994-07-27 Hoechst Aktiengesellschaft Use of leflunomid for the inhibition of tumor necrosis factor alpha
WO1994024095A1 (en) * 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
WO1998042338A1 (en) * 1997-03-21 1998-10-01 Hoechst Aktiengesellschaft Extension of the expression of transgenic proteins by immunomodulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES448386A1 (en) * 1975-06-05 1978-04-16 Hoechst Ag 5-Methyl-isoxazole-4-carboxylic acid anilides
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
AU712679B2 (en) * 1994-07-01 1999-11-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607775A2 (en) * 1993-01-08 1994-07-27 Hoechst Aktiengesellschaft Use of leflunomid for the inhibition of interleukin 1 beta
EP0607776A2 (en) * 1993-01-08 1994-07-27 Hoechst Aktiengesellschaft Use of leflunomid for the inhibition of tumor necrosis factor alpha
WO1994024095A1 (en) * 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
WO1998042338A1 (en) * 1997-03-21 1998-10-01 Hoechst Aktiengesellschaft Extension of the expression of transgenic proteins by immunomodulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J.K. LIM ET AL.: "Analgesic, Anti-inflammatory and Antiviral Effects of Melandrin Derivatives", YAKHAK HOECHI, vol. 38, no. 3, 1994, pages 345 - 350, XP002115339 *
MCCHESNEY L P ET AL: "An evaluation of leflunomide in the canine renal transplantation model.", TRANSPLANTATION, (1994 JUN 27) 57 (12) 1717-22., XP002115338 *
WALDMAN W J (REPRINT) ET AL: "Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide", TRANSPLANTATION, (15 APR 1999) VOL. 67, NO. 7, PP. 825-825. PUBLISHER: LIPPINCOTT WILLIAMS & WILKINS, 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106. ISSN: 0041-1337., OHIO STATE UNIV, DEPT PATHOL, COLUMBUS, OH 43210;RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT SURG, CHICAGO, IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT IMMUNOL MICROBIOL, CHICAGO, IL 60612, XP002115336 *
WALDMAN, W. J. (1) ET AL: "Inhibition of cytomegalovirus by the immunosuppressive agent leflunomide.", FASEB JOURNAL, (MARCH 20, 1998) VOL. 12, NO. 5, PP. A808. MEETING INFO.: ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY 98, PART II SAN FRANCISCO, CALIFORNIA, USA APRIL 18-22, 1998 FEDERATION OF AMERICAN SOCIETIES FOR, XP002115337 *

Also Published As

Publication number Publication date
ATE382349T1 (en) 2008-01-15
DE69937904T2 (en) 2009-01-02
EP1169036A2 (en) 2002-01-09
EP1169036B1 (en) 2008-01-02
WO1999045908A2 (en) 1999-09-16
DE69937904D1 (en) 2008-02-14
HK1045251A1 (en) 2002-11-22
JP2003523309A (en) 2003-08-05
AU3080299A (en) 1999-09-27
JP4581137B2 (en) 2010-11-17

Similar Documents

Publication Publication Date Title
WO1999064047A8 (en) Novel antiviral compounds
ZA991856B (en) Storage-stable compositions useful for the production of structural foams.
WO2001004273A3 (en) Glucoamylase variant
AU2001280887A1 (en) Listing items globally and regionally, and customized listing according to currency on shipping area
WO2001096537A3 (en) Pre-oxidized alpha-amylase
WO2001060157A3 (en) Antibacterial agents and compositions
CA2359654A1 (en) Clear fabric softener formulations
ZA963567B (en) Enzymatic detergent compositions.
SG116428A1 (en) Multiple polymeric additive systems: compositions,processes, and products thereof.
ZA991469B (en) Improvement in or relating to organic compositions.
WO2002044322A3 (en) Bacteriophage composition useful in treating food products to prevent bacterial contamination
MXPA01005745A (en) Toxicity typing using embryoid bodies.
ZA99495B (en) Wiping article which exhibits differential wet extensibility characteristics.
EP1065261A3 (en) Detergent compositions comprising a retrograded starch degrading enzyme
ZA969769B (en) Enzymatic detergent compositions.
MXPA03009868A (en) Coating compositions comprising high t-area carbon products.
CA2327784A1 (en) Triazolones with a neuroprotective action
HK1045251A1 (en) Anti-viral uses of leflunomide products
MXPA01010026A (en) Aqueous coating composition with improved adhesion to friable surfaces.
WO1998041097A3 (en) Non-retrograding starch in food products
ZA992372B (en) Strain of the microorganism penicillium oxalicum var. Armeniaca and its application.
WO2002044310A3 (en) Granular conditioning product
AU5180899A (en) Embellishing articles
WO1998058246A3 (en) Improvements in and relating to compounds, sensors and extractants
ZA200205260B (en) Compositions for the manufacture of organo-mineral products, products obtained therefrom and their use.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09529053

Country of ref document: US

122 Ep: pct application non-entry in european phase
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 535323

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1999912426

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999912426

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999912426

Country of ref document: EP